H5N1 News and Research

Latest H5N1 News and Research

Strategy that dismantles flu viral genome in human lung cells ensures safe research

A new strategy that dismantles a viral genome in human lung cells will ensure safe research on deadly strains of influenza, say researchers from the Icahn School of Medicine at Mount Sinai.

13 Aug 2013

NanoViricides, LRRI sign NDA for IND-enabling efficacy studies on FluCide drug candidates

NanoViricides, Inc. said it has signed a non-disclosure agreement with the Lovelace Respiratory Research Institute. The Company intends to enter into a Master Services Agreement with LRRI for the IND-enabling efficacy studies of both its broad-spectrum injectable and oral FluCide drug candidates.

5 Aug 2013

Sir Michael Stratton, Thijn Brummelkamp and Anne Glover to speak at The EMBO Meeting 2013

Predisposition to cancer and other diseases, genetic testing, infectious proteins and ubiquitin signalling -- these are some of the topics internationally renowned speakers will tackle at The EMBO Meeting 2013 to be held in Amsterdam, the Netherlands, from 21-24 September 2013.

22 Jul 2013

Some strains of avian H7N9 influenza develop resistance to antiviral drugs

Some strains of the avian H7N9 influenza that emerged in China this year have developed resistance to the only antiviral drugs available to treat the infection, but testing for antiviral resistance can give misleading results, helping hasten the spread of resistant strains.

17 Jul 2013

H7 influenza may spillover repeatedly into humans, say scientists

The H7N9 avian flu strain that emerged in China earlier this year has subsided for now, but it would be a mistake to be reassured by this apparent lull in infections. The virus has several highly unusual traits that paint a disquieting picture of a pathogen that may yet lead to a pandemic, according to lead scientists from the National Institute of Allergy and Infectious Diseases.

10 Jul 2013

Seattle researchers map critical molecules that regulate inflammation during flu infection

The influenza virus' ability to mutate quickly has produced new, emerging strains that make drug discovery more critical than ever. For the first time, researchers at Seattle BioMed, along with collaborators at the University of California, San Diego School of Medicine, St. Jude Children's Research Hospital and the University of Washington, have mapped how critical molecules regulate both the induction and resolution of inflammation during flu infection.

6 Jul 2013

Study describes radiologic findings in H7N9 pneumonia

H7N9 pneumonia is characterized by imaging findings that differentiate it from other types of pneumonia, including rapidly progressive changes in the lungs and pulmonary connective tissues, according to the first study to describe radiologic findings in the disease. The results are published online in the journal Radiology.

2 Jul 2013

NanoViricides submits letter of intent to file Orphan Drug Application with EMA for DengueCide

NanoViricides, Inc. announced today that it has submitted its letter of intent to file an Orphan Drug Application with the European Medicines Agency for DengueCide, its drug candidate for the treatment of dengue and dengue hemorrhagic fever.

1 Jul 2013

Medicago produces Rotavirus VLP vaccine candidate using plant-based manufacturing platform

Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced the successful production of a Rotavirus VLP vaccine candidate comprising all four structural antigens of rotavirus (VP2, VP4, VP6 and VP7) using Medicago's plant-based manufacturing platform.

20 Jun 2013

Medicago gets Health Canada clearance to initiate Phase II clinical trial for H5N1 vaccine

Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today announced it has received clearance by Health Canada to initiate its Phase II dose-sparing clinical trial for an H5N1 Avian Influenza VLP vaccine candidate ("H5N1 vaccine").

11 Jun 2013

NanoViricides files Orphan Drug application with FDA for DengueCide

NanoViricides, Inc. announced today that it has filed an Orphan Drug application with the Office of Orphan Product Development of the US FDA for DengueCide, its drug candidate for the treatment of dengue and dengue hemorrhagic fever.

10 Jun 2013

Medicago reports positive interim results from preclinical trial for H7 VLP vaccine candidate

Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today reported positive interim results from a preclinical trial for an H7N9 Avian Influenza VLP vaccine candidate ("H7 vaccine").

6 Jun 2013

Researchers develop new gene therapy to thwart potential influenza pandemic

Researchers at the Perelman School of Medicine, University of Pennsylvania have developed a new gene therapy to thwart a potential influenza pandemic. Specifically, investigators in the Gene Therapy Program, Department of Pathology and Laboratory Medicine, directed by James M. Wilson, MD, PhD, demonstrated that a single dose of an adeno-associated virus expressing a broadly neutralizing flu antibody into the nasal passages of mice and ferrets gives them complete protection and substantial reductions in flu replication when exposed to lethal strains of H5N1 and H1N1 flu virus.

30 May 2013

Sinovac Beijing receives GMP certificate for its proprietary vaccines

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced that Sinovac Beijing, the main operating subsidiary company of Sinovac, obtained the Certificate of Good Manufacturing Practices for Pharmaceutical Products (GMP Certificate) from the China State and Food Administration (CFDA) for its proprietary vaccines, its Haidian district bulk production plants, and its Changping filing and packaging facility.

24 May 2013

New, improved drugs can boost body's natural flu killer system

A known difficulty in fighting influenza (flu) is the ability of the flu viruses to mutate and thus evade various medications that were previously found to be effective. Researchers at the Hebrew University of Jerusalem have shown recently that another, more promising, approach is to focus on improving drugs that boost the body's natural flu killer system.

24 May 2013

iBio announces production of vaccine candidate for new H7N9 influenza virus

iBio, Inc. today announced the production of a vaccine candidate for the newly emerged H7N9 influenza virus by an independent third party laboratory using the iBioLaunch platform.

22 May 2013

A*STAR, Cytos Biotechnology provide update on Phase 1 clinical trial of H1N1 influenza vaccine

Singapore's Agency for Science, Technology and Research and Switzerland's Cytos Biotechnology AG today announced that the first healthy volunteer has been dosed in a Phase 1 clinical trial with their H1N1 influenza vaccine candidate based on Cytos' proprietary bacteriophage Qbeta virus-like particle technology.

17 May 2013

New VLP vaccine candidate produced for H7N9 virus

Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today announced that it has successfully produced a new VLP vaccine candidate for the H7N9 virus that is responsible for the current influenza outbreak in China.

8 May 2013

Researchers call H7N9 bird flu strain 'one of the most lethal'; first case outside China reported by Taiwan

Chinese scientists have confirmed for the first time that a new strain of bird flu that has killed 23 people in China has been transmitted to humans from chickens.

26 Apr 2013

Nature editorial, opinion piece address H7N9 virus

The journal Nature published an editorial and opinion piece on the emergence of the H7N9 avian influenza strain.

26 Apr 2013

H5N1 News and Research

Latest H5N1 News and Research

Strategy that dismantles flu viral genome in human lung cells ensures safe research

NanoViricides, LRRI sign NDA for IND-enabling efficacy studies on FluCide drug candidates

Sir Michael Stratton, Thijn Brummelkamp and Anne Glover to speak at The EMBO Meeting 2013

Some strains of avian H7N9 influenza develop resistance to antiviral drugs

H7 influenza may spillover repeatedly into humans, say scientists

Seattle researchers map critical molecules that regulate inflammation during flu infection

Study describes radiologic findings in H7N9 pneumonia

NanoViricides submits letter of intent to file Orphan Drug Application with EMA for DengueCide

Medicago produces Rotavirus VLP vaccine candidate using plant-based manufacturing platform

Medicago gets Health Canada clearance to initiate Phase II clinical trial for H5N1 vaccine

NanoViricides files Orphan Drug application with FDA for DengueCide

Medicago reports positive interim results from preclinical trial for H7 VLP vaccine candidate

Researchers develop new gene therapy to thwart potential influenza pandemic

Sinovac Beijing receives GMP certificate for its proprietary vaccines

New, improved drugs can boost body's natural flu killer system

iBio announces production of vaccine candidate for new H7N9 influenza virus

A*STAR, Cytos Biotechnology provide update on Phase 1 clinical trial of H1N1 influenza vaccine

New VLP vaccine candidate produced for H7N9 virus

Researchers call H7N9 bird flu strain 'one of the most lethal'; first case outside China reported by Taiwan

Nature editorial, opinion piece address H7N9 virus

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

H5N1 News and Research

Latest H5N1 News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in